002437 Stock Overview
Harbin Gloria Pharmaceuticals Co., Ltd engages in the research, development, production, and sale of pharmaceutical products primarily in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
HARBIN GLORIA PHARMACEUTICALS Co., LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.68 |
| 52 Week High | CN¥2.99 |
| 52 Week Low | CN¥1.66 |
| Beta | 0.43 |
| 1 Month Change | 4.69% |
| 3 Month Change | 45.65% |
| 1 Year Change | 8.50% |
| 3 Year Change | 0.75% |
| 5 Year Change | -9.15% |
| Change since IPO | -32.24% |
Recent News & Updates
HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Nov 08
HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Solid Earnings May Rest On Weak Foundations
Nov 04Recent updates
HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Nov 08HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Solid Earnings May Rest On Weak Foundations
Nov 04Insufficient Growth At HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Hampers Share Price
Jul 03Why HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Earnings Are Better Than They Seem
Apr 22Shareholder Returns
| 002437 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -6.3% | -4.3% | -3.5% |
| 1Y | 8.5% | -3.4% | 10.9% |
Return vs Industry: 002437 exceeded the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 002437 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 002437 volatility | |
|---|---|
| 002437 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002437 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002437's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3,085 | Leifeng Guo | www.gloria.cc |
Harbin Gloria Pharmaceuticals Co., Ltd engages in the research, development, production, and sale of pharmaceutical products primarily in the People’s Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People’s Republic of China.
HARBIN GLORIA PHARMACEUTICALS Co., LTD Fundamentals Summary
| 002437 fundamental statistics | |
|---|---|
| Market cap | CN¥6.11b |
| Earnings (TTM) | CN¥80.20m |
| Revenue (TTM) | CN¥2.43b |
76.2x
P/E Ratio2.5x
P/S RatioIs 002437 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002437 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.43b |
| Cost of Revenue | CN¥1.12b |
| Gross Profit | CN¥1.31b |
| Other Expenses | CN¥1.23b |
| Earnings | CN¥80.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.035 |
| Gross Margin | 53.83% |
| Net Profit Margin | 3.30% |
| Debt/Equity Ratio | 2.3% |
How did 002437 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 11:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HARBIN GLORIA PHARMACEUTICALS Co., LTD is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Shanshan Li | China Merchants Securities Co. Ltd. |